|
Gonzalez-Calle V, Rodriguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, Gonzalez-Rodriguez AP, Gonzalez Y, Oriol A, Martinez-Lopez J, Gonzalez MS, Hernandez MT, Sirvent M, Cedena T, Puig N, Paiva B, Blade J, Lahuerta JJ, San-Miguel JF, Mateos MV. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study. Haematologica. 2024 Jul 1;109(7):2219-2228. doi: 10.3324/haematol.2023.284089. PubMed PMID: 38356463; PubMed Central PMCID: PMC11215366.
AÑO: 2024; IF: 7.9
|
38356463
|
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosinol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Blade J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Espanol de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatias Malignas) cooperative study group. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. PubMed PMID: 38684670; PubMed Central PMCID: PMC11059156.
AÑO: 2024; IF: 11.6
|
|
Lakhwani S, Mateos MV, Martinez-Lopez J, Paiva B, Rosinol Dachs L, Martinez R, Oriol A, Bargay J, Gonzalez-Montes Y, Gironella M, Encinas C, Martin J, Jarque I, Granell M, Abella E, Garcia-Mateo A, Hernandez-Rivas JA, Ramila E, Krsnik I, Casado Montero LF, De Arriba F, Palomera L, Sampol A, Moraleda JM, Casanova M, Delgado P, Lafuente A, Amutio E, Lopez-Martinez A, Altes A, Ruiz MA, Alegre A, Lopez-Anglada L, De La Cruz J, Alonso Fernandez R, Blade Creixenti J, Lahuerta JJ, San-Miguel J, Hernandez MT. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease. Ann Hematol. 2024 Dec;103(12):5651-5661. doi: 10.1007/s00277-024-06031-0. Epub 2024 Oct 23. PubMed PMID: 39438321.
AÑO: 2024; IF: 2.4
|
|
Gonzalez-Calle V, Rodriguez-Otero P, Calasanz MJ, Guijarro M, Martinez-Lopez J, Rosinol L, Hernandez MT, Teruel AI, Gironella M, Oriol A, de la Rubia J, Gonzalez-Rodriguez AP, Bargay J, de Arriba F, Palomera L, Gonzalez-Perez MS, Sureda A, Ocio E, Lahuerta JJ, Blade J, San Miguel JF, Mateos MV, Gutierrez NC. High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. Hemasphere. 2024 Dec 10;8(12):e70031. doi: 10.1002/hem3.70031. eCollection 2024 Dec. PubMed PMID: 39665068; PubMed Central PMCID: PMC11632121.
AÑO: 2024; IF: 14.6
|
|
Guerrero C, Puig N, Cedena MT, Calasanz MJ, Gutierrez NC, Fernandez M, Oriol A, Rios-Tamayo R, Hernandez MT, Martinez-Martinez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Gonzalez Perez MS, Orfao A, Mateos MV, Martinez-Lopez J, Rosinol L, Blade J, Lahuerta JJ, San-Miguel JF, Paiva B. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024 Feb 15;143(7):597-603. doi: 10.1182/blood.2023022083. PubMed PMID: 38048552.
AÑO: 2024; IF: 23.1
|